The institute is a collaborative effort of Fred Hutch Cancer Center and UW Medicine. A natural outgrowth of established research and clinical collaborations, the IPCR brings together a world-renowned ...

The prostate cancer research effort in PGJCCR is delivered by an experienced team of multidisciplinary researchers with a strong clinical and translational emphasis. PROSTATE CANCER Prostate cancer is ...

Natural Supplement Supports Prostate Function, Bladder Comfort, and Urinary Flow for Men Seeking Daily Wellness Tallmadge, June 07, 2025 (GLOBE NEWSWIRE) -- ProstaCleanse , a men's wellness brand ...

Jay Harris on his prostate cancer diagnosis. Harris, the familiar face in sports journalism, known for his insightful commentary and engaging delivery, recently appeared in an interview with Michael ...

Prostate Cancer Screening Ages 40 to 54 The PSA test is a blood test that measures how much of a particular protein (called prostate-specific antigen) is in your blood. It’s been the standard for ...

Prostate cancer (PCa) is a major health concern world-wide, being the most common cancer and the third leading cause of cancer-related deaths in men after lung and colorectal cancers. Projections ...

Prostate cancer is the second most common cancer in men and the fifth most common cause of cancer death in men worldwide. In 2022, an estimated 1.5 million men were diagnosed with prostate cancer, and ...

In an interview with Targeted Oncology TM, Alicia Morgans, MD, MPH, genitourinary medical oncologist at Dana-Farber Cancer Center in Boston, Massachusetts, discusses the phase 3 ARASTEP study ...

1 Introduction. Lung cancer represents a primary cause of global cancer-related mortality, responsible for approximately 631,000 deaths annually (Siegel et al., 2021).Contrary to trends in Western ...

Akeega is a fixed-dose combination of GSK’s PARP inhibitor Zejula—to which J&J owns prostate cancer rights—and Zytiga. Despite the positive readout from the phase 3 Amplitude trial, ...

Today's biotech news covers Pluvicto's prostate cancer play, J&J's big bets on bladder, lung, and talent, and more. Skip to Main Content Manage alerts for this article ...